Hypertrophic cardiomyopathy in MYBPC3 carriers in aging
The Journal of Cardiovascular Aging · 11.01.2024 · 4 (1)
DOI: 10.20517/jca.2023.29 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Cardiovascular Aging, online erschienen am 11.01.2024. Verfasst von Kalyani Ananthamohan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH 45267, USA. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 336 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Hypertrophic cardiomyopathy (HCM) is characterized by abnormal thickening of the myocardium, leading to arrhythmias, heart failure, and elevated risk of sudden cardiac death, particularly among the young. This inherited disease is predominantly caused by mutations in sarcomeric genes, among which those in the cardiac myosin binding protein-C3 (MYBPC3 ) gene are major contributors. HCM associated with MYBPC3 mutations usually presents in the elderly and ranges from asymptomatic to symptomatic forms, affecting numerous cardiac functions and presenting significant health risks with a spectrum of clinical manifestations. Regulation of MYBPC3 expression involves various transcriptional and translational mechanisms, yet the destiny of mutant MYBPC3 mRNA and protein in late-onset HCM remains unclear. Pathogenesis related to MYBPC3 mutations includes nonsense-mediated decay, alternative splicing, and ubiquitin-proteasome system events, leading to allelic imbalance and haploinsufficiency. Aging further exacerbates the severity of HCM in carriers of MYBPC3 mutations. Advancements in high-throughput omics techniques have identified crucial molecular events and regulatory disruptions in cardiomyocytes expressing MYBPC3 variants. This review assesses the pathogenic mechanisms that promote late-onset HCM through the lens of transcriptional, post-transcriptional, and post-translational modulation of MYBPC3 , underscoring its significance in HCM across carriers. The review also evaluates the influence of aging on these processes and MYBPC3 levels during HCM pathogenesis in the elderly. While pinpointing targets for novel medical interventions to conserve cardiac function remains challenging, the emergence of personalized omics offers promising avenues for future HCM treatments, particularly for late-onset cases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati, Cincinnati, OH 45267, USA.
- Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University, Cleveland, OH 45267, USA.
ORCID-Profile: Kalyani Ananthamohan, Sakthivel Sadayappan
Förderung
- NIAMS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Ananthamohan, K., Stelzer, J. E., & Sadayappan, S. (2024). Hypertrophic cardiomyopathy in MYBPC3 carriers in aging. The Journal of Cardiovascular Aging, 4(1). https://doi.org/10.20517/jca.2023.29
Vancouver
Ananthamohan K, Stelzer JE, Sadayappan S. Hypertrophic cardiomyopathy in MYBPC3 carriers in aging. The Journal of Cardiovascular Aging. 2024;4(1). doi:10.20517/jca.2023.29
BibTeX
@article{Ananthamohan2024,
author = {Ananthamohan, Kalyani and Stelzer, Julian E and Sadayappan, Sakthivel},
title = {Hypertrophic cardiomyopathy in MYBPC3 carriers in aging},
journal = {The Journal of Cardiovascular Aging},
year = {2024},
volume = {4},
number = {1},
doi = {10.20517/jca.2023.29}
}
EUVIMED